TBX2 protein acts as a switch to drive prostate cancer treatment resistance, study finds
According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during ...
CURE1d
FDA Expands Pluvicto Indication in Prostate Cancer Subset
FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...
Healio1d
FDA expands Pluvicto indication for earlier use in patients with prostate cancer
The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...
2NVS : FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...
Fierce Pharma1d
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
CURE8d
First Patent Dosed With Pocenbrodib in Trial for Metastatic Prostate Cancer
First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...
Applied Clinical Trials Online1d
FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto
Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...
Targeted Oncology13d
Analyzing AE Data to Guide Selection of Androgen Receptor Inhibitors in mHSPC
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
MedPage Today on MSN1d
Alarm Over HHS Changes; Exercise and Cancer Risk; No Surgery for Breast Cancer?
The Trump administration's reorganization of HHS, combined with significant reductions in workforce, could jeopardize ...
EurekAlert!12d
Rice statistician earns $1 million CPRIT award to advance AI-powered precision medicine for prostate cancer
Rice statistician Erzsébet Merényi is part of a team of researchers awarded $1 million by the Cancer Prevention and Research Institute of Texas to develop AI tools that can identify lethal forms of ...